Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD
pharmacotherapies offer only modest transient cognitive and behavioral benefits …

The amyloid cascade hypothesis is a useful framework for therapeutic development in
Alzheimer's disease (AD). Amyloid b 1-42 (Aβ) has been the main target of experimental …

Introduction Alzheimer's disease (AD) is the most common cause of dementia worldwide,
making it a major public health issue. Anti-amyloid and anti-tau antibodies are the most …

The clinical benefit associated with anti-amyloid immunotherapies, a new class of drugs for
the treatment of Alzheimer's disease, is predicated on their ability to modify disease course …

To review the optimality and safety of different anti‐Amyloid‐β (Aβ) immunotherapies for
Alzheimer's disease (AD). Published randomized controlled trials were comprehensively …

In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for
Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results …

Background: In a previous review article in the Taiwanese Journal of Psychiatry (Takeda
and Tagami: Taiwanese J. Psychiatry 2020; 34: 152-61), we gave the development status of …

The amyloid hypothesis, that established amyloid-β (Aβ) peptide as the primary cause of
Alzheimer's disease (AD) and related dementia, has driven the development of treatments …

In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for
Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results …

Background: Available drugs for the global Alzheimer disease (AD) epidemic only treat the
symptoms without modifying disease progression. Accumulating evidence supports amyloid …